Legend Biotech Corp. ADR (LEGN) News
Filter LEGN News Items
LEGN News Results
|Loading, please wait...|
LEGN News Highlights
- LEGN's 30 day story count now stands at 11.
- Over the past 10 days, the trend for LEGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about LEGN are DRUG, FUTU and JNJ.
Latest LEGN News From Around the Web
Below are the latest news stories about Legend Biotech Corp that investors may wish to consider to help them evaluate LEGN as an investment opportunity.
Legend Biotech (LEGN) has reported preliminary results for 2021, expecting loss of ~$365.3M to $397.4M and adj. loss of $335.8M to $364.7M.As of Dec
SOMERSET, N.J., February 18, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the year ended December 31, 2021.
The stock market appears to be making a transition in the these first few months of 2022, from last year’s bullish trend to a slower pace of growth this year. Headwinds are mounting – the pandemic is stubbornly persistent, inflation is high and trending higher, the Fed is getting set to raise interest rates in response, the list goes on – and so it’s natural for retail investors and experts alike to go looking for advice on how to navigate these difficult currents. And one source of advice is the circle of market gurus, the hedge fund experts who have leveraged their insight into multi-billion dollar success.
The FDA has instituted a clinical hold on Legend Biotech Corporation''s (NASDAQ: LEGN ) Phase 1 trial for LB1901. LB1901 is the company''s investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The … Full story available on Benzinga.com
Legend Biotech (LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration ((FDA)) imposed a clinical hold on its Phase…
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The FDA indicated they would provide an official clinical hold letter to Legend Biotech by March 11. Related content: Benzinga's Full FDA Calendar. To date, one patient has been dosed in the clinical trial
SOMERSET, N.J., February 15, 2022--Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
Legend Biotech (LEGN) announced the achievement of two milestones under its collaboration with Janssen Biotech of Johnson & Johnson (JNJ) for cilta-cel.Also called…
SOMERSET, N.J., February 11, 2022--Legend Biotech has achieved milestone payments under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel).
Investment company Yong Rong (HK) Asset Management Ltd (Current Portfolio) buys Futu Holdings, XPeng Inc, Pinduoduo Inc, Taiwan Semiconductor Manufacturing Co, Luckin Coffee Inc, sells Advanced Micro Devices Inc, Freeport-McMoRan Inc, Marathon Digital Holdings Inc, Affirm Holdings Inc, Recursion Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Yong Rong (HK) Asset Management Ltd.